SPINRAZA Solution for injection (2020)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Spinraza 12 mg solution for injection.
Qualitative and quantitative composition
Each 5 ml vial contains nusinersen sodium equivalent to 12 mg nusinersen. Each ml contains 2.4 mg of nusinersen. For the full list of excipients, see section 6.1.
Pharmaceutical form
Solution for injection. Clear and colourless solution with pH of approximately 7.2.
Therapeutic indications
Spinraza is indicated for the treatment of 5q Spinal Muscular Atrophy.
Posology and method of administration
Treatment with Spinraza should only be initiated by a physician with experience in the management of spinal muscular atrophy (SMA). The decision to treat should be based on an individualised expert evaluation ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Special warnings and precautions for use
Lumbar puncture procedure There is a risk of adverse reactions occurring as part of the lumbar puncture procedure (e.g. headache, back pain, vomiting; see section 4.8). Potential difficulties with this ...
Interaction with other medicinal products and other forms of interaction
No interaction studies have been performed. In vitro studies indicated that nusinersen is not an inducer or inhibitor of CYP450 mediated metabolism. In vitro studies indicate that the likelihood for interactions ...
Fertility, pregnancy and lactation
Pregnancy There are no or limited amount of data from the use of nusinersen in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see ...
Effects on ability to drive and use machines
Spinraza has no or negligible influence on the ability to drive and use machines .
Undesirable effects
Summary of safety profile The safety assessment of Spinraza was based on two Phase 3 clinical studies in infants (CS3B) and children (CS4) with SMA, together with one Phase 2 study in infants and children ...
Overdose
No cases of overdose associated with adverse reactions were reported in clinical studies. In the event of an overdose, supportive medical care should be provided including consulting with a healthcare ...
Pharmacodynamic properties
Pharmacotherapeutic group: Other drugs for disorders of the musculo-skeletal system ATC code: M09AX07 Mechanism of action Nusinersen is an antisense oligonucleotide (ASO) which increases the proportion ...
Pharmacokinetic properties
Single- and multiple-dose pharmacokinetics (PK) of nusinersen, administered via intrathecal injection, were determined in paediatric patients diagnosed with SMA. Absorption Intrathecal injection of nusinersen ...
Preclinical safety data
Carcinogenesis Long-term studies in animals to evaluate the carcinogenic potential of nusinersen have not been performed. Mutagenesis Nusinersen demonstrated no evidence of genotoxicity. Reproductive toxicity ...
List of excipients
Sodium dihydrogen phosphate dihydrate Disodium phosphate Sodium chloride Potassium chloride Calcium chloride dihydrate Magnesium chloride hexahydrate Sodium hydroxide (for pH adjustment) Hydrochloric acid ...
Incompatibilities
Not applicable.
Shelf life
3 years.
Special precautions for storage
Store in a refrigerator (2°C-8°C). Do not freeze. Keep the vial in the outer carton in order to protect from light. If no refrigeration is available, Spinraza may be stored in its original carton, protected ...
Nature and contents of container
5 ml in a Type I glass vial with bromobutyl rubber stopper and an aluminium over-seal and plastic cap. Pack size of one vial per carton.
Special precautions for disposal and other handling
For single use only. Instructions for preparation of the medicinal product before administration: The Spinraza vial should be inspected for particles prior to administration. If particles are observed ...
Marketing authorization holder
Biogen Netherlands B.V., Prins Mauritslaan 13, 1171 LP Badhoevedorp, The Netherlands
Marketing authorization number(s)
EU/1/17/1188/001
Date of first authorization / renewal of the authorization
Date of first authorisation: 30 May 2017
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
